MEDINET Co., Ltd. (2370.T)
JPY 31.0
(0.0%)
JPY 31.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 781 Thousand JPY | -66.15% |
| 2022 | 2.3 Million JPY | -46.35% |
| 2021 | 4.3 Million JPY | -44.09% |
| 2020 | 7.69 Million JPY | -38.13% |
| 2019 | 12.43 Million JPY | -57.75% |
| 2018 | 29.42 Million JPY | -59.91% |
| 2017 | 73.38 Million JPY | -59.61% |
| 2016 | 181.67 Million JPY | 25.81% |
| 2015 | 144.4 Million JPY | 187.59% |
| 2014 | 50.21 Million JPY | 4.66% |
| 2013 | 47.98 Million JPY | -95.36% |
| 2012 | 1.03 Billion JPY | -1.47% |
| 2011 | 1.05 Billion JPY | 2.87% |
| 2010 | 1.02 Billion JPY | 18807.48% |
| 2009 | 5.4 Million JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | - JPY | 0.0% |
| 2024 Q1 | - JPY | 0.0% |
| 2024 Q2 | - JPY | 0.0% |
| 2023 Q2 | - JPY | 0.0% |
| 2023 Q3 | - JPY | 0.0% |
| 2023 Q4 | 781 Thousand JPY | 0.0% |
| 2023 Q1 | - JPY | -100.0% |
| 2023 FY | 781 Thousand JPY | -66.15% |
| 2022 Q1 | - JPY | -100.0% |
| 2022 FY | 2.3 Million JPY | -46.35% |
| 2022 Q4 | 2.3 Million JPY | 0.0% |
| 2022 Q3 | - JPY | 0.0% |
| 2022 Q2 | - JPY | 0.0% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 FY | 4.3 Million JPY | -44.09% |
| 2021 Q4 | 4.3 Million JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2020 Q4 | 7.69 Million JPY | 0.0% |
| 2020 FY | 7.69 Million JPY | -38.13% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q1 | - JPY | -100.0% |
| 2019 Q1 | - JPY | -100.0% |
| 2019 Q4 | 12.43 Million JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 FY | 12.43 Million JPY | -57.75% |
| 2018 Q4 | 29.42 Million JPY | 0.0% |
| 2018 Q3 | - JPY | -100.0% |
| 2018 Q2 | 75 Million JPY | 0.0% |
| 2018 Q1 | - JPY | -100.0% |
| 2018 FY | 29.42 Million JPY | -59.91% |
| 2017 Q4 | 73.38 Million JPY | -60.86% |
| 2017 Q2 | 75 Million JPY | 0.0% |
| 2017 Q3 | 187.5 Million JPY | 150.0% |
| 2017 FY | 73.38 Million JPY | -59.61% |
| 2017 Q1 | 75 Million JPY | -58.72% |
| 2016 Q1 | 500 Million JPY | 246.24% |
| 2016 Q2 | 500 Million JPY | 0.0% |
| 2016 Q3 | 75 Million JPY | -85.0% |
| 2016 Q4 | 181.67 Million JPY | 142.23% |
| 2016 FY | 181.67 Million JPY | 25.81% |
| 2015 FY | 144.4 Million JPY | 187.59% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 Q1 | - JPY | -100.0% |
| 2015 Q4 | 144.4 Million JPY | 0.0% |
| 2015 Q3 | - JPY | 0.0% |
| 2014 Q3 | - JPY | 0.0% |
| 2014 Q2 | - JPY | 0.0% |
| 2014 Q1 | - JPY | -100.0% |
| 2014 FY | 50.21 Million JPY | 4.66% |
| 2014 Q4 | 50.21 Million JPY | 0.0% |
| 2013 Q2 | - JPY | -100.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 Q4 | 47.98 Million JPY | 0.0% |
| 2013 FY | 47.98 Million JPY | -95.36% |
| 2013 Q1 | 1 Billion JPY | -3.37% |
| 2012 Q3 | 1 Billion JPY | 0.0% |
| 2012 Q4 | 1.03 Billion JPY | 3.49% |
| 2012 FY | 1.03 Billion JPY | -1.47% |
| 2012 Q1 | 1 Billion JPY | -4.79% |
| 2012 Q2 | 1 Billion JPY | 0.0% |
| 2011 FY | 1.05 Billion JPY | 2.87% |
| 2011 Q1 | 1 Billion JPY | -2.06% |
| 2011 Q2 | 1 Billion JPY | 0.0% |
| 2011 Q3 | 1 Billion JPY | 0.0% |
| 2011 Q4 | 1.05 Billion JPY | 5.03% |
| 2010 Q1 | - JPY | -100.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | 1.02 Billion JPY | 18807.48% |
| 2010 Q4 | 1.02 Billion JPY | 2.1% |
| 2010 Q3 | 1 Billion JPY | 0.0% |
| 2009 FY | 5.4 Million JPY | 0.0% |
| 2009 Q2 | - JPY | 0.0% |
| 2009 Q4 | 5.4 Million JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | 99.898% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 99.961% |
| Linical Co., Ltd. | 1.49 Billion JPY | 99.948% |
| Trans Genic Inc. | 1.32 Billion JPY | 99.941% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 99.967% |
| AnGes, Inc. | 214.94 Million JPY | 99.637% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 99.269% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 99.999% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | 99.076% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 99.93% |
| Carna Biosciences, Inc. | 28.4 Million JPY | 97.25% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | 99.911% |
| RaQualia Pharma Inc. | 39.05 Million JPY | 98.0% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 99.958% |
| PeptiDream Inc. | 19.63 Billion JPY | 99.996% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | 99.515% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | 99.803% |
| Healios K.K. | 450 Million JPY | 99.826% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | 98.99% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | 99.899% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | 99.901% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | 99.841% |
| StemCell Institute Inc. | 6.67 Million JPY | 88.301% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | 99.457% |